IL104063A0 - Methods and compositions for reducing multi-drug resistance - Google Patents
Methods and compositions for reducing multi-drug resistanceInfo
- Publication number
- IL104063A0 IL104063A0 IL104063A IL10406392A IL104063A0 IL 104063 A0 IL104063 A0 IL 104063A0 IL 104063 A IL104063 A IL 104063A IL 10406392 A IL10406392 A IL 10406392A IL 104063 A0 IL104063 A0 IL 104063A0
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- drug resistance
- reducing multi
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80518691A | 1991-12-10 | 1991-12-10 | |
US98276692A | 1992-12-07 | 1992-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL104063A0 true IL104063A0 (en) | 1993-05-13 |
Family
ID=27122756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL104063A IL104063A0 (en) | 1991-12-10 | 1992-12-10 | Methods and compositions for reducing multi-drug resistance |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0616493A4 (zh) |
JP (1) | JPH07502274A (zh) |
CN (1) | CN1076358A (zh) |
AU (1) | AU3243393A (zh) |
CA (1) | CA2125279A1 (zh) |
IL (1) | IL104063A0 (zh) |
MX (1) | MX9207150A (zh) |
WO (1) | WO1993011668A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681812A (en) * | 1991-12-10 | 1997-10-28 | Rush Presbyterian-St. Luke's Medical Center | Methods and compositions for reducing multidrug resistance |
CA2130025A1 (en) * | 1993-08-25 | 1995-02-26 | Robert B. Peery | Method of treating fungal infections |
CA2190636A1 (en) * | 1994-05-19 | 1995-11-30 | John S. Coon | Methods and compositions for reducing multidrug resistance |
US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
WO2000053231A2 (en) * | 1999-03-09 | 2000-09-14 | Protarga, Inc. | Fatty acid-anticancer conjugates and uses thereof |
US7235583B1 (en) | 1999-03-09 | 2007-06-26 | Luitpold Pharmaceuticals, Inc., | Fatty acid-anticancer conjugates and uses thereof |
WO2000067802A1 (en) * | 1999-05-10 | 2000-11-16 | Protarga, Inc. | Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof |
DE10115740A1 (de) | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3919411A (en) * | 1972-01-31 | 1975-11-11 | Bayvet Corp | Injectable adjuvant and compositions including such adjuvant |
US4889525A (en) * | 1982-08-17 | 1989-12-26 | Adamantech, Inc. | Sensitization of hypoxic tumor cells and control of growth thereof |
US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4563351A (en) * | 1983-08-01 | 1986-01-07 | Forsyth Dental Infirmary For Children | Self-gelling therapeutic compositions for topical application |
SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
US4978622A (en) * | 1986-06-23 | 1990-12-18 | Regents Of The University Of California | Cytophaga-derived immunopotentiator |
JP2558107B2 (ja) * | 1986-12-18 | 1996-11-27 | 第一製薬株式会社 | 外用剤 |
US4863968A (en) * | 1987-04-09 | 1989-09-05 | Merrell Dow Pharmaceuticals Inc. | Methods of treating gout with chalcone derivatives |
US4753965A (en) * | 1987-04-09 | 1988-06-28 | Merrell Dow Pharmaceuticals, Inc. | Method of treating multiple sclerosis with chalcone derivatives |
US4904697A (en) * | 1987-04-09 | 1990-02-27 | Merrell Dow Pharmaceuticals Inc. | Controlling the growth of certain tumor tissue with chalcone derivatives |
US4978332A (en) * | 1987-09-28 | 1990-12-18 | Matrix Pharmaceutical, Inc. | Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas |
US5108989A (en) * | 1990-04-04 | 1992-04-28 | Genentech, Inc. | Method of predisposing mammals to accelerated tissue repair |
-
1992
- 1992-12-09 JP JP5511010A patent/JPH07502274A/ja active Pending
- 1992-12-09 EP EP19930900961 patent/EP0616493A4/en not_active Withdrawn
- 1992-12-09 CA CA002125279A patent/CA2125279A1/en not_active Abandoned
- 1992-12-09 WO PCT/US1992/010563 patent/WO1993011668A1/en not_active Application Discontinuation
- 1992-12-09 AU AU32433/93A patent/AU3243393A/en not_active Abandoned
- 1992-12-10 IL IL104063A patent/IL104063A0/xx unknown
- 1992-12-10 MX MX9207150A patent/MX9207150A/es unknown
- 1992-12-10 CN CN92115397A patent/CN1076358A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
MX9207150A (es) | 1993-12-01 |
EP0616493A1 (en) | 1994-09-28 |
AU3243393A (en) | 1993-07-19 |
CN1076358A (zh) | 1993-09-22 |
EP0616493A4 (en) | 1994-11-09 |
CA2125279A1 (en) | 1993-06-24 |
WO1993011668A1 (en) | 1993-06-24 |
JPH07502274A (ja) | 1995-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9525977D0 (en) | Perfluoroelastomeric compositions and methods | |
IL104107A0 (en) | New compounds and compositions | |
GB9121289D0 (en) | Composition and use | |
EP0540357A3 (en) | Protein-silicone copolymers and compositions containing them | |
KR950013580B1 (en) | Method and compositions for difusion patierning | |
IL101281A0 (en) | Anti-cancer compounds and compositions | |
SG42865A1 (en) | Therapeutic compositions and methods | |
EP0499233A3 (en) | Organopentasiloxane and method for its preparation | |
ZA921279B (en) | Substituted alpha-aminoaldehydes and derivatives | |
EP0510591A3 (en) | Polymer compositions and their blends | |
IL104063A0 (en) | Methods and compositions for reducing multi-drug resistance | |
ZA943649B (en) | Piperidine derivatives their preparation and use | |
GB9021911D0 (en) | Compositions and methods for weight reduction | |
ZA924491B (en) | Compositions and use thereof | |
ZA921137B (en) | Composition and use | |
GB9224295D0 (en) | Method and composition | |
ZA929596B (en) | Methods and compositions for reducing multi-drug resistance. | |
IL113542A0 (en) | Substituted hydroxybenzyl-heteroaryl derivatives compositions containing them and their use | |
ZA922146B (en) | Inorganic perbromide compositions and methods for use thereof | |
GB9026896D0 (en) | Method and composition | |
GB9111824D0 (en) | Method and composition | |
GB9308051D0 (en) | Method and composition | |
GB9116906D0 (en) | Composition and use | |
GB9108695D0 (en) | Pharmaceutical method and compositions | |
GB9108647D0 (en) | Pharmaceutical method and compositions |